EE04275B1 - Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid - Google Patents

Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid

Info

Publication number
EE04275B1
EE04275B1 EEP200000613A EEP200000613A EE04275B1 EE 04275 B1 EE04275 B1 EE 04275B1 EE P200000613 A EEP200000613 A EE P200000613A EE P200000613 A EEP200000613 A EE P200000613A EE 04275 B1 EE04275 B1 EE 04275B1
Authority
EE
Estonia
Prior art keywords
processes
preparation
pharmaceutical compositions
quinoline derivatives
quinoline
Prior art date
Application number
EEP200000613A
Other languages
English (en)
Estonian (et)
Inventor
Bj�rk Anders
J�nsson Stig
Fex Tomas
Hedlund Gunnar
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of EE200000613A publication Critical patent/EE200000613A/xx
Publication of EE04275B1 publication Critical patent/EE04275B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EEP200000613A 1998-04-27 1999-04-26 Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid EE04275B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9801474A SE9801474D0 (sv) 1998-04-27 1998-04-27 Quinoline Derivatives
PCT/SE1999/000676 WO1999055678A1 (en) 1998-04-27 1999-04-26 Quinoline derivatives

Publications (2)

Publication Number Publication Date
EE200000613A EE200000613A (et) 2002-04-15
EE04275B1 true EE04275B1 (et) 2004-04-15

Family

ID=20411103

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000613A EE04275B1 (et) 1998-04-27 1999-04-26 Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid

Country Status (33)

Country Link
EP (1) EP1073639B1 (cs)
JP (1) JP4045069B2 (cs)
KR (1) KR100571534B1 (cs)
CN (1) CN1113057C (cs)
AP (1) AP1293A (cs)
AT (1) ATE228505T1 (cs)
AU (1) AU747550B2 (cs)
BR (1) BR9909925B1 (cs)
CA (1) CA2329788C (cs)
CZ (1) CZ297439B6 (cs)
DE (1) DE69904162T2 (cs)
DK (1) DK1073639T3 (cs)
EE (1) EE04275B1 (cs)
ES (1) ES2188242T3 (cs)
HK (1) HK1036618A1 (cs)
HR (1) HRP20000726B1 (cs)
HU (1) HU227709B1 (cs)
ID (1) ID26277A (cs)
IL (2) IL138160A0 (cs)
IS (1) IS2082B (cs)
ME (1) ME00870B (cs)
NO (1) NO315606B1 (cs)
NZ (1) NZ506641A (cs)
OA (1) OA11547A (cs)
PL (1) PL190441B1 (cs)
PT (1) PT1073639E (cs)
RS (1) RS50029B (cs)
RU (1) RU2197481C2 (cs)
SE (1) SE9801474D0 (cs)
TR (1) TR200003061T2 (cs)
UA (1) UA60354C2 (cs)
WO (1) WO1999055678A1 (cs)
ZA (1) ZA200004601B (cs)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) * 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
KR100908655B1 (ko) 2002-11-27 2009-07-21 엘지디스플레이 주식회사 데이터 공급시간의 변조방법과 이를 이용한액정표시장치의 구동방법 및 장치
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SE0401578D0 (sv) * 2004-06-18 2004-06-18 Active Biotech Ab Novel compounds
US7838522B2 (en) 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
US7973039B2 (en) 2004-12-21 2011-07-05 Merck Serono Sa Sulfonyl amino cyclic derivatives and use thereof
JP4950070B2 (ja) 2005-01-31 2012-06-13 メルク セローノ ソシエテ アノニム N−ヒドロキシアミド誘導体及びその使用
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 jnk 억제제
WO2007025991A2 (en) 2005-09-01 2007-03-08 Ares Trading S.A. Treatment of optic neuritis
CN103333107A (zh) * 2005-10-19 2013-10-02 泰华制药工业有限公司 拉奎尼莫钠晶体及其制备方法
BRPI0713694A2 (pt) * 2006-06-12 2012-10-30 Teva Pharma composição farmacêutica, processo para preparar composição farmacêutica, embalagens vedada, métodos para tratar um indivìduo afligido com uma forma de esclerose múltipla, e para aliviar um sintoma de esclerose múltipla em um indivìduo afligido com uma forma de esclerose múltipla, e, uso da composição farmacêutica
EP2682120B1 (en) 2007-12-20 2016-08-03 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
NZ591315A (en) * 2008-09-03 2012-08-31 Teva Pharma 2-oxo-1,2-dihydro-quinoline modulators of immune function
KR20120045032A (ko) * 2009-07-30 2012-05-08 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 크론병의 치료
HUE029983T2 (en) 2009-08-10 2017-04-28 Teva Pharma Treatment of BDNF-related diseases with laquinimod
PT2542079E (pt) * 2010-03-03 2014-07-18 Teva Pharma Tratamento da artrite reumatoide com uma combinação de laquinimod e metotrexato
EA201290837A1 (ru) 2010-03-03 2013-05-30 Тева Фармасьютикал Индастриз Лтд. Лечение волчаночного нефрита с применением лаквинимода
WO2011109536A1 (en) * 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of lupus arthritis using laquinimod
WO2011116091A1 (en) 2010-03-17 2011-09-22 Novartis Ag Dispenser
JP5881691B2 (ja) 2010-07-09 2016-03-09 アクティブ バイオテック エイビー キノリン−3−カルボキサミドの製造方法
EP3213636A1 (en) * 2010-07-09 2017-09-06 Teva Pharmaceutical Industries, Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
MX2013000332A (es) * 2010-07-09 2013-02-26 Teva Pharma 5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-dihidroquinolina-3-ca rboxamida, sales y usos de la misma.
EP2444086A1 (en) 2010-10-22 2012-04-25 Almirall, S.A. Combinations comprising DHODH inhibitors and COX inhibitors
KR20140101333A (ko) 2011-10-12 2014-08-19 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드 및 핑골리모드의 조합을 이용한 다발성 경화증의 치료
TW201345527A (zh) * 2012-02-03 2013-11-16 Teva Pharma 拉喹莫德於治療對第一線抗-TNFα療法無效之克隆氏症患者之用途
MX2014009889A (es) 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺
TW201400117A (zh) * 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療gaba媒介之疾病之拉喹莫德(laquinimod)
US8975279B2 (en) 2012-11-07 2015-03-10 Teva Pharmaceutical Industries, Ltd. Amine salts of laquinimod
RU2545056C2 (ru) * 2012-12-10 2015-03-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здавоохранения и социального развития Российской Федерации (ГБОУ ВПО ПГФА Минздравсоцразвития России) Противовоспалительное и анальгетическое средство на основе изопропиламида 1,2-дигидро-1н-2-оксоцинхониновой кислоты
MX2015010296A (es) * 2013-02-15 2016-05-05 Teva Pharma Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
KR20150143499A (ko) 2013-03-14 2015-12-23 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드 나트륨의 결정 및 이의 개선된 제조방법
AU2015253330A1 (en) 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
US9956212B2 (en) 2014-09-23 2018-05-01 Active Biotech Ab Quinoline carboxamides for use in the treatment of multiple myeloma
KR102525805B1 (ko) 2014-11-19 2023-04-25 액티브 바이오테크 에이비 백혈병 치료용 퀴놀린 카르복사미드
DK3886858T3 (da) 2019-12-19 2022-08-22 Active Biotech Ab Forbindelser til behandling af øjensygdomme forbundet med for megen vaskularisering
WO2021175924A1 (en) 2020-03-03 2021-09-10 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
KR20230043916A (ko) 2020-07-23 2023-03-31 에라스무스 유니버시티 메디컬 센터 로테르담 골수증식성 신생물의 새로운 치료학적 표적으로서 s100 단백질
AU2022208424A1 (en) 2021-01-18 2023-08-24 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
KR20240012436A (ko) 2021-05-25 2024-01-29 액티브 바이오테크 에이비 복수의 타스퀴니모드 입자 및 그 용도
WO2023275248A1 (en) 2021-07-02 2023-01-05 Active Biotech Ab A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives

Also Published As

Publication number Publication date
SE9801474D0 (sv) 1998-04-27
EP1073639B1 (en) 2002-11-27
DK1073639T3 (da) 2003-03-24
BR9909925B1 (pt) 2010-09-21
HUP0102084A2 (hu) 2001-11-28
CZ297439B6 (cs) 2006-12-13
ES2188242T3 (es) 2003-06-16
IS5615A (is) 2000-08-31
CA2329788C (en) 2004-11-23
ME00870B (me) 2008-11-28
CN1298393A (zh) 2001-06-06
IS2082B (is) 2006-02-15
ATE228505T1 (de) 2002-12-15
EP1073639A1 (en) 2001-02-07
HRP20000726B1 (en) 2009-04-30
PT1073639E (pt) 2003-04-30
DE69904162T2 (de) 2003-08-21
HUP0102084A3 (en) 2002-12-28
NO315606B1 (no) 2003-09-29
CN1113057C (zh) 2003-07-02
NO20005254D0 (no) 2000-10-19
IL138160A0 (en) 2001-10-31
BR9909925A (pt) 2001-01-09
AP2000001933A0 (en) 2000-12-31
NO20005254L (no) 2000-12-27
JP2002513006A (ja) 2002-05-08
EE200000613A (et) 2002-04-15
RU2197481C2 (ru) 2003-01-27
OA11547A (en) 2004-05-24
AU4301399A (en) 1999-11-16
JP4045069B2 (ja) 2008-02-13
CA2329788A1 (en) 1999-11-04
IL138160A (en) 2006-04-10
AP1293A (en) 2004-08-30
UA60354C2 (uk) 2003-10-15
HK1036618A1 (en) 2002-01-11
WO1999055678A1 (en) 1999-11-04
ZA200004601B (en) 2002-02-27
NZ506641A (en) 2002-03-28
CZ20003849A3 (cs) 2001-03-14
DE69904162D1 (de) 2003-01-09
AU747550B2 (en) 2002-05-16
PL190441B1 (pl) 2005-12-30
RS50029B (sr) 2008-11-28
TR200003061T2 (tr) 2001-01-22
PL343420A1 (en) 2001-08-13
ID26277A (id) 2000-12-14
HU227709B1 (en) 2011-12-28
KR100571534B1 (ko) 2006-04-14
HRP20000726A2 (en) 2001-04-30
YU61200A (sh) 2003-07-07

Similar Documents

Publication Publication Date Title
EE04275B1 (et) Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid
EE04464B1 (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE200100431A (et) 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine
EE04673B1 (et) Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid
NO20001409L (no) Karboksamidotiazolderivater, fremgangsmÕte for fremstilling derav og farmasøytiske blandinger
EE9500064A (et) Asendatud 1H-imidasoolid, nende valmistamismeetodid ja farmatseutilised kompositsioonid
EE05081B1 (et) Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, 3-aminoasetidiini derivaadid ja nende valmistamise meetodid
EE200200487A (et) Asetidiini derivaadid, nende valmistamismeetodid ja farmatseutiline kompositsioon
EE200200095A (et) Sulfonüülkarboksamiidi derivaadid, nende kasutamine, ravim ja nende valmistamismeetod
EE200100252A (et) Pürimidiinderivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja sellevalmistamismeetod, kombinatsioon ning saadus
EE04721B1 (et) Fenüülksantiini derivaadid, nende valmistamismeetodid ja kasutamine
HUP0105133A3 (en) Quinoline derivatives and quinazoline derivatives, pharmaceutical compositions containing them and their use
EE04915B1 (et) Kinuklidiinderivaadid, nende valmistamismeetod, vahehendid, farmatseutiline kompositsioon ja nende kasutamine
EE03680B1 (et) Asendatud püridiinid, nende kasutamine ja farmatseutilised kompositsioonid
EE200000707A (et) Oksasolidinooni derivaadid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
EE200300207A (et) Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon
EE04276B1 (et) Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid
NO20016038D0 (no) Benzenderivater, fremgangsmåte for deres fremstilling og farmasöytiske preparater inneholdende de samme
EE200000596A (et) Tienüülasolüülalkoksüetaanamiinderivaadid, nende ja nende soolade valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja kasutamine ning vaheühend ja selle valmistamismeetod
HUP0102766A3 (en) Aminomethylcarboxylic acid derivatives, their pharmaceutical use and pharmaceutical compositions comprising them
DK1128831T3 (da) Farmaceutisk moxifloxacinpræparat
EE200000037A (et) Atsüülpiperasinüülpürimidiinide derivaadid, nende valmistamine ja kasutamine ravimitena
EE9800302A (et) Arüülglütsiinamiidi derivaadid, nende valmistamismeetod ja kasutamine ning farmatseutiline preparaat
EE03825B1 (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE04346B1 (et) Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231